Show Stocks and Investing Publications • Fri, September 9, 2022
Andrew Galler Initiated (ARWR) at Hold and Held Target at $41 on, Sep 9th, 2022
rew-galler-initiated-arwr-at-hold-and-held-target-at-41-on-sep-9th-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAIAndrew Galler of Morgan Stanley, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold and Held Target at $41 on, Sep 9th, 2022.
Andrew has made no other calls on ARWR in the last 4 months.
There are 6 other peers that have a rating on ARWR. Out of the 6 peers that are also analyzing ARWR, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $35 on, Wednesday, May 11th, 2022
These are the ratings of the 5 analyists that currently disagree with Andrew
- Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $65 on, Monday, August 8th, 2022
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $110 on, Friday, June 3rd, 2022
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $72 on, Wednesday, May 11th, 2022
- Joel Beatty of "Baird" Upgraded from Hold to Buy and Decreased Target to $60 on, Wednesday, May 11th, 2022
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $80 on, Wednesday, May 11th, 2022
Like: 👍